Arsanis, Inc. Receives Grant from the Austrian Research Promotion Agency for Pre-Clinical and Clinical Development of Monoclonal Antibodies Against Severe Nosocomial Infections
10/19/2011 10:52:30 AM
VIENNA--(BUSINESS WIRE)--Arsanis Biosciences GmbH, an early stage biotechnology company developing anti-infective human monoclonal antibodies, today announced the award of a grant for the development of monoclonal antibody therapeutics against nosocomial infections from the Austrian Research Promotion Agency (Forschungs-Förderungs-Gesellschaft or “FFG”), the leading public funding agency for translational research in Austria. The support from FFG for the first year is 1.19 million EUR; additional funding (up to 70% of the total budget of 12.5 million EUR for the program) is expected in the following three years.
comments powered by